Bildkälla: Stockfoto

Medivir Q4 2024: TTP Continues to Improve - Redeye

Redeye reviews Medivir's fourth quarter report, which disclosed further improvements in patient survival. After the two recent equity issues, the company is well funded to continue developing fostrox towards a phase IIb trial.

Redeye reviews Medivir's fourth quarter report, which disclosed further improvements in patient survival. After the two recent equity issues, the company is well funded to continue developing fostrox towards a phase IIb trial.
Börsvärldens nyhetsbrev
ANNONSER